Ni J, Hong J, Liang X, Dai J, Long Z, Luan C
Res Pract Thromb Haemost. 2024; 8(7):102578.
PMID: 39628651
PMC: 11613164.
DOI: 10.1016/j.rpth.2024.102578.
Elsayed A, Elsayed B, Elmarasi M, Elsabagh A, Elsayed E, Elmakaty I
Immunotargets Ther. 2024; 13:461-486.
PMID: 39290805
PMC: 11407319.
DOI: 10.2147/ITT.S463384.
Zhou M, Li T, Zhang P, Lai Y, Sheng L, Ouyang G
Ann Hematol. 2024; 103(5):1697-1704.
PMID: 38536476
DOI: 10.1007/s00277-024-05711-1.
Muntion S, Preciado S, Sanchez-Luis E, Corchete L, Diez-Campelo M, Osugui L
Ther Adv Hematol. 2023; 13:20406207221142137.
PMID: 36601635
PMC: 9806379.
DOI: 10.1177/20406207221142137.
Kircali E, Seval G, Ozturk C, Yilmaz H, Koyun D, Bozdag S
Balkan Med J. 2022; 40(1):51-56.
PMID: 36571427
PMC: 9874246.
DOI: 10.4274/balkanmedj.galenos.2022.2022-2-48.
Avatrombopag for the treatment of thrombocytopenia post hematopoietic stem-cell transplantation.
Zhou M, Qi J, Gu C, Wang H, Zhang Z, Wu D
Ther Adv Hematol. 2022; 13:20406207221127532.
PMID: 36185780
PMC: 9523859.
DOI: 10.1177/20406207221127532.
Efficacy of Eltrombopag in Children with Post-Stem Cell Transplant Prolonged Isolated Thrombocytopenia.
Matsumoto M, Terada K, Tsuchimochi T, Takahashi S, Noguchi Y, Igarashi S
Hematol Rep. 2022; 14(3):240-244.
PMID: 35997400
PMC: 9396996.
DOI: 10.3390/hematolrep14030033.
Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature.
Bortolotti M, Pettine L, Zaninoni A, Croci G, Barcellini W, Fattizzo B
Pharmaceuticals (Basel). 2022; 15(4).
PMID: 35455416
PMC: 9032708.
DOI: 10.3390/ph15040419.
Thrombocytopenia and Therapeutic Strategies after Allogeneic Hematopoietic Stem Cell Transplantation.
Bento L, Canaro M, Bastida J, Sampol A
J Clin Med. 2022; 11(5).
PMID: 35268455
PMC: 8911458.
DOI: 10.3390/jcm11051364.
Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients.
Ahn H, Byun J, Kim I, Youk J, Koh Y, Shin D
J Korean Med Sci. 2022; 37(6):e48.
PMID: 35166084
PMC: 8845101.
DOI: 10.3346/jkms.2022.37.e48.
Eltrombopag in the treatment of patients with persistent thrombocytopenia after haploidentical peripheral blood stem cell transplantation: a single-center experience.
Yan F, Lu N, Gu Z, Huang W, Wang S, Gao X
Ann Hematol. 2021; 101(2):397-408.
PMID: 34735613
DOI: 10.1007/s00277-021-04706-6.
Role of Thrombopoietin Receptor Agonists in Inherited Thrombocytopenia.
Bastida J, Gonzalez-Porras J, Rivera J, Lozano M
Int J Mol Sci. 2021; 22(9).
PMID: 33919295
PMC: 8122256.
DOI: 10.3390/ijms22094330.
Phase I Dose-Finding, Safety, and Tolerability Trial of Romiplostim to Improve Platelet Recovery After UCB Transplantation.
Christakopoulos G, DeFor T, Hage S, Wagner J, Linden M, Brunstein C
Transplant Cell Ther. 2021; 27(6):497.e1-497.e6.
PMID: 33785364
PMC: 8217114.
DOI: 10.1016/j.jtct.2021.02.033.
The Thrombopoietin Receptor Agonist Eltrombopag Inhibits Human Cytomegalovirus Replication Via Iron Chelation.
Vogel J, Schmidt S, Schmidt D, Rothweiler F, Koch B, Baer P
Cells. 2019; 9(1).
PMID: 31861948
PMC: 7017049.
DOI: 10.3390/cells9010031.
Eltrombopag maintains human hematopoietic stem and progenitor cells under inflammatory conditions mediated by IFN-γ.
Alvarado L, Huntsman H, Cheng H, Townsley D, Winkler T, Feng X
Blood. 2019; 133(19):2043-2055.
PMID: 30803992
PMC: 6509545.
DOI: 10.1182/blood-2018-11-884486.
